Learning Objectives OPA Home Study Educational Programming: Patient Safety, Law & Immunization

Objectives for OPF Home-Study Continuing Education

Patient/Medication Safety Home-Study CPE

Medication Error Reporting
ACPE #0129-0000-21-033-H05-P
Objectives: At the completion of this activity, the participant will be able to:

1. describe the importance of reporting medication errors in an accurate and timely manner;
2. differentiate between active, mandatory, and passive/voluntary reporting mechanisms; and
3. apply the steps necessary to report a medication error.

Medication Safety: Minimizing Patient Harm
ACPE #0129-0000-21-046-H05-P
Objectives: At the completion of this activity, the participant will be able to:

1. identify important resources in the literature, such as To Err is Human, that helped stimulate a focus on medication safety in hospitals;
2. describe Just Culture principles, and their importance in healthcare institutions; and
3. identify roles pharmacists play in patient and medication safety at different levels of healthcare

Ensuring Medication Safety Through REMS Programs
ACPE #0129-0000-20-006-H05-P
Objectives: At the completion of this activity, the participant will be able to:

1. recognize the purpose of the FDA REMS program in relation to the safe use of medications;
2. list the components of a REMS program that may be utilized to help providers balance the benefits of medications versus the risks;
3. identify counseling methods that focus on relaying medication safety information to patients; and
4. demonstrate an understanding of the requirements that pharmacies may need to fulfill to dispense REMS medications and protect patient safety.

Outpatient Insulin Errors and Mitigation Strategies
ACPE #0129-0000-21-093-H05-P
Objectives: At the completion of this activity, the participant will be able to:

1. recognize the prevalence of and contributing factors to insulin errors;
2. list the different types of insulin errors and situations in which they can occur; and
3. select strategies to reduce insulin errors in various situations and settings.

Vaccine Administration Errors and Prevention Strategies
ACPE #0129-0000-22-014-H05-P
Objectives: At the completion of this activity, the participant will be able to:

1. differentiate between vaccine error reporting systems and vaccine adverse event reporting systems;
2. identify common vaccine errors surrounding the SARS-CoV-2 (COVID-19) vaccines;
3. list new formulations of the pneumococcal vaccine recently released to market; and
4. recognize strategies to prevent future errors related to vaccines.

---

Law Home-Study CPE

Pharmacist Dispensing of Naloxone, Insulin, and Epinephrine Autoinjectors
ACPE #0129-0000-20-013-H03-P
Objectives: At the completion of this activity, the participant will be able to:

1. list the circumstances in which a pharmacist may dispense naloxone, insulin, or epinephrine autoinjectors without a prescription in an emergency situation;
2. recognize the labeling and documentation requirements when dispensing naloxone, insulin, or epinephrine autoinjectors without a prescription in an emergency;
3. demonstrate an understanding of the legal and professional requirements to consult and educate the patient on the proper use of these medications; and
4. identify the requirements for substituting a less expensive epinephrine autoinjector for a prescribed product.

Institutional Pharmacy Practice Rules Revision
ACPE Program #0129-0000-21-013-H03-P
Objectives: At the completion of this activity, the participant will be able to:

1. list practice areas that can be defined as an institutional facility;
2. identify minimum standards and record keeping requirements of Chapter 4729:5-9 of the Ohio Administrative Code (OAC);
3. recognize patient profile and drug utilization review requirements of Chapter 4729:5-9 of the Ohio Administrative Code (OAC);
4. identify the requirements for valid medication orders, custom packaging and drug repackaging in an institutional facility; and
5. outline security requirements for use of contingency drug supplies and automated storage systems in institutional facilities.

2022 Updates to Ohio Pharmacy Laws and Rules
ACPE #0129-0000-22-013-H03-P
Objectives: At the completion of this activity, the participant will be able to:

1. list the mandatory electronic prescribing requirement for schedule II controlled substances;
2. recognize when pharmacists must obtain an OARRS report when presented with a prescription;
3. select the requirements for pharmacists to dispense nicotine replacement therapy per a physician- authorized protocol;
4. recognize how many days’ worth of medication a pharmacist may provide a patient when their prescription on file does not have refills remaining; and
5. list the requirements for performing pharmacy functions remotely in Ohio.

---

Immunization Home-Study CPE

Vaccine-Preventable Diseases: Overview and Recommended Immunizations
ACPE #0129-0000-20-062-H06-P
Objectives: At the completion of this activity, the participant will be able to:

1. demonstrate knowledge of the immune system, types of antigens, and types of immunity;
2. identify effective immunization strategies for prevention of influenza, pneumonia, hepatitis A & B, meningitis, tetanus, diphtheria, pertussis, varicella, herpes zoster, measles, mumps, rubella, Haemophilus influenzae Type b (Hib), polio, and human papillomavirus (HPV) in at-risk populations, and the role healthcare providers play;
3. demonstrate an understanding of the currently available vaccines for the diseases discussed, including indications, dosing recommendations, contraindications and precautions, adverse reactions, and storage requirements;
4. outline how to appropriately monitor for and treat adverse reactions, including the use of epinephrine and diphenhydramine;
5. recognize how to report vaccine adverse events; and
6. list key resources for current information on vaccines.

---

Long-Acting Injectables Home-Study CPE

Injectable Cobalamin Review for Pharmacists
ACPE #0129-0000-21-076-H01-P
Objectives: At the completion of this activity, the participant will be able to:

1. identify the mechanism of action of cobalamin and etiology of cobalamin deficiency;
2. demonstrate an understanding of appropriate treatment of cobalamin deficiency, including affected patient populations, dosages, administration schedules, routes of administration, and storage;
3. list adverse reactions, precautions, and contraindications of cobalamin injections, as well as monitoring and treatment of patients who experience an allergic reaction; and
4. recognize patient concerns that may arise, including patient privacy and storage of patient-specific medications in the pharmacy.

Injectable Medroxyprogesterone Acetate Review for Pharmacists
ACPE #0129-0000-21-078-H01-P
Objectives: At the completion of this activity, the participant will be able to:

1. recognize the therapeutic role of medroxyprogesterone acetate in contraception;
2. identify pharmacokinetic and pharmacodynamic properties of medroxyprogesterone acetate;
3. list precautions, warnings, contraindications, and adverse reactions of medroxyprogesterone acetate; and recognize appropriate treatment for severe allergic reactions; and
4. demonstrate an understanding of the appropriate dosing and administration of medroxyprogesterone acetate.

Injectable Hydroxyprogesterone Caproate Review for Pharmacists
ACPE #0129-0000-21-077-H01-P
Objectives: At the completion of this activity, the participant will be able to:

1. identify patients who are indicated to receive hydroxyprogesterone caproate injection;
2. identify contraindications to hydroxyprogesterone caproate therapy;
3. demonstrate an understanding of proper storage and administration of hydroxyprogesterone caproate injection; and
4. recognize common adverse reactions associated with hydroxyprogesterone injections and how to manage them.

Long-Acting Injectable Antipsychotics Review for Pharmacists
ACPE #0129-0000-21-079-H01-P
Objectives: At the completion of this activity, the participant will be able to:

1. recognize the therapeutic role of long-acting injectable antipsychotics and demonstrate an understanding of the disorders they are used to treat;
2. demonstrate an understanding of mechanisms of action and appropriate dosing and administration of long-acting injectable antipsychotics;
3. list precautions, contraindications, and adverse reactions of long-acting injectable antipsychotics; and recognize appropriate treatment for severe allergic reactions; and
4. recognize the importance of acute and chronic monitoring for these medications

Review of Injectable Extended-Release Naltrexone and Buprenorphine
ACPE #0129-0000-21-080-H01-P
Objectives: At the completion of this activity, the participant will be able to:

1. identify the indication(s), mechanism of action, dose, preparation and administration of ER naltrexone and ER buprenorphine;
2. list the adverse effects, precautions, and contraindications of ER naltrexone and ER buprenorphine;
3. recognize the appropriate monitoring parameters for patients receiving ER naltrexone and ER buprenorphine; and
4. demonstrate an understanding of evidence-based treatment plans for the use of ER naltrexone in the treatment of alcohol and opioid use disorder and ER buprenorphine in the treatment of opioid use disorder